vTv Therapeutics Inc.
VTVT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641489
No open-market purchases or sales by vTv Therapeutics Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $60.5M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by vTv Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for vTv Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Baker Julian | Director | 135,946Indirect | Jun 29, 2026 | 1 |
| Baker Felix | Director | 135,946Indirect | Jun 29, 2026 | 1 |
| Baker Bros. Advisors LP | Director | 135,946Indirect | Jun 29, 2026 | 1 |
| Baker Brothers Life Sciences LP | Director | 135,946Indirect | Jun 29, 2026 | 1 |
| 667, L.P. | Director | 135,946Indirect | Jun 29, 2026 | 1 |
| Baker Bros. Advisors (GP) LLC | Director | 135,946Indirect | Jun 29, 2026 | 1 |
| Spiegelman Daniel K | Director | – | Jun 29, 2026 | 1 |
| Akkaraju Srinivas | Director | 106,000Indirect | Jun 29, 2026 | 1 |
| Phillips Anne M. | Director | – | Jun 29, 2026 | 1 |
| Al-Marzooqi Fahed | Director | – | Jun 29, 2026 | 1 |
| Sekhri Paul J | Pres, CEO and Exec Chairperson | 5,000 | Feb 18, 2026 | 1 |
| Tung Michael Stephen | EVP & CFO | – | Feb 18, 2026 | 1 |
| Samsara BioCapital, L.P. | 10% Owner | 206,784Indirect | Dec 6, 2024 | 0 |
| Samsara BioCapital GP, LLC | 10% Owner | 206,784Indirect | Dec 6, 2024 | 0 |
| Tuch Steven L. | Chief Financial Officer | – | Jun 13, 2024 | 0 |
| Kozlov Hersh | Director | – | Jun 21, 2023 | 0 |
| Fry John A | Director | 61,000 | Jun 21, 2023 | 0 |
| Weiner Howard L. | Director | – | Jun 21, 2023 | 0 |
| Harris Keith R. | Director | – | Jun 21, 2023 | 0 |
| Harjivan Chandresh | Director | – | Jun 21, 2023 | 0 |
| Isaacsohn Jonathan | Director | – | Jun 21, 2023 | 0 |
| Nelson Rich S. | Acting Chief Executive Officer | – | Mar 4, 2022 | 0 |
| Perelman Ronald O | 10% Owner | 36,519,212Indirect | Dec 21, 2021 | 0 |
| Prasad Deepa | President and CEO | – | Oct 21, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 19, 2024 (view filing) | Nov 15-18 | 4 days | Sekhri Paul JPres, CEO and Exec Chairperson | PPurchaseClass A Common Stock | +5.00K | $16.76 | +$83.8K | New position5.00K after | 3 lots10b5-1 |
| Nov 30, 2022 (view filing) | Nov 28-29 | 2 days | Fry John ADirector | PPurchaseClass A common stock | +61.0K | $0.83 | +$50.6K | New position61.0K after | 2 lots |
| Dec 21, 2021 (view filing) | Dec 20 | 1 day | Perelman Ronald O10% Owner | SSaleClass A Common Stock | −87.0K | $1.15 | −$100.0K | −0.2%36.5M after |